GO:1905601 negative regulation of receptor-mediated endocytosis involved in cholesterol transport: Cholesterol Uptake Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905601 describes any process that stops, prevents, or reduces the frequency, rate, or extent of receptor-mediated endocytosis involved in cholesterol transport.
• This biological process is central to cellular cholesterol homeostasis and is best understood in the context of LDL receptor (LDLR) trafficking and vascular endothelial biology.
• Dysregulation of this process contributes to atherosclerosis, where endothelial dysfunction and altered lipoprotein handling promote plaque formation.
• Inflammatory signals, including endotoxin exposure, can modulate intestinal and systemic lipid handling, indirectly affecting cholesterol transport pathways.
• Key protein players include LDLR, PCSK9, IDOL, ARH, and clathrin-associated machinery, which together tune receptor availability at the plasma membrane.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of this regulatory node in cholesterol uptake.
Description
Cholesterol is essential for membrane integrity, steroid hormone synthesis, and bile acid production, yet excess cholesterol is cytotoxic and pro-atherogenic. Cells therefore tightly control cholesterol acquisition, in part by regulating the endocytic uptake of low-density lipoprotein (LDL) particles through the LDL receptor (LDLR). GO:1905601, negative regulation of receptor-mediated endocytosis involved in cholesterol transport, captures the inhibitory arm of this control system: the processes that reduce or prevent LDLR-mediated internalization of cholesterol-carrying particles. Understanding this term matters because it defines a key checkpoint that determines how much cholesterol enters a cell and how much remains in circulation. In vascular endothelium, the balance between uptake and retention of lipoproteins is directly linked to atherosclerosis initiation and progression. Moreover, systemic inflammatory states, such as those triggered by endotoxin, can alter intestinal function and lipid handling, indirectly influencing cholesterol transport and its regulation. Researchers studying metabolic disease, cardiovascular biology, and lipoprotein trafficking therefore need precise tools to manipulate and measure this regulatory process.
negative regulation of receptor-mediated endocytosis involved in cholesterol transport At A Glance
| GO ID | GO:1905601 |
|---|---|
| GO term | negative regulation of receptor-mediated endocytosis involved in cholesterol transport |
| Ontology | biological_process |
| Synonym | inhibition of receptor-mediated endocytosis of LDL; downregulation of receptor-mediated endocytosis of low-density lipoprotein particle involved in cholesterol transport |
| Major function | Reduces or prevents receptor-mediated endocytosis of cholesterol-carrying particles, thereby limiting cellular cholesterol uptake |
| Related process | Receptor-mediated endocytosis involved in cholesterol transport (positive counterpart) |
| Key receptors | LDLR and related lipoprotein receptors |
| Disease relevance | Atherosclerosis and vascular endothelial dysfunction |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, imaging, biochemical uptake assays |
What Is GO:1905601?
GO:1905601 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of receptor-mediated endocytosis involved in cholesterol transport. In practice, it refers to the negative regulation of the endocytic pathway by which cells internalize cholesterol-bearing particles, most notably LDL, via specific cell-surface receptors such as LDLR. This includes molecular events that decrease receptor availability, inhibit receptor clustering or internalization, or divert receptors away from the endocytic route. The term is not about cholesterol synthesis or efflux; it is specifically about dampening the receptor-mediated uptake step that delivers exogenous cholesterol into the cell.
Why Is negative regulation of receptor-mediated endocytosis involved in cholesterol transport Important in Cell Biology?
GO:1905601 is important because it defines a regulatory brake on cholesterol uptake, and the strength of that brake directly influences plasma cholesterol levels, endothelial lipid handling, and atherosclerotic risk. When negative regulation fails or is bypassed, excessive LDLR-mediated endocytosis can overload cells with cholesterol, while excessive negative regulation can leave cholesterol in circulation, promoting vascular injury. Inflammatory and infectious states can further perturb these pathways, as seen with endotoxin effects on intestinal function and systemic metabolism. Thus, this term provides a conceptual and experimental anchor for studying how cells and tissues balance cholesterol acquisition under normal and pathological conditions.
• Controls cellular cholesterol acquisition by limiting LDLR-mediated uptake.
• Protects cells from cholesterol overload and lipotoxicity.
• Shapes plasma LDL levels and cardiovascular risk.
• Modulates endothelial function and atherosclerosis initiation.
• Integrates with inflammatory signaling that affects lipid handling.
• Provides a target for therapeutic modulation of cholesterol uptake.
• Helps explain inter-individual variation in response to lipid-lowering strategies.
• Guides CRISPR-based functional genomics of lipoprotein trafficking.
• Connects intestinal function and systemic lipid metabolism under endotoxin challenge.
• Supports development of cell models for metabolic and vascular disease research.
What Happens During negative regulation of receptor-mediated endocytosis involved in cholesterol transport?
Receptor availability at the plasma membrane
In simple terms: The cell controls how many LDL receptors are on its surface, and fewer receptors mean less cholesterol uptake.
The first step in negative regulation is reducing the number of functional receptors available for ligand binding at the plasma membrane. This can occur through decreased receptor recycling, enhanced receptor degradation, or altered trafficking that keeps receptors away from the cell surface. In endothelial and other cells, such changes lower the capacity for LDL internalization and thus dampen cholesterol transport.
Ligand-receptor interaction and clustering
In simple terms: Even if receptors are present, the cell can prevent them from gathering into the clusters needed for uptake.
Receptor-mediated endocytosis requires LDL particles to bind LDLR and for receptors to cluster in clathrin-coated pits. Negative regulation can interfere with this clustering or with the stability of ligand-receptor complexes, reducing the efficiency of internalization. This step is a key control point because it acts before membrane invagination and vesicle formation.
Endocytic vesicle formation and trafficking
In simple terms: The cell can slow or stop the formation and movement of the vesicles that carry cholesterol inward.
After clustering, the membrane invaginates and pinches off to form endocytic vesicles. Negative regulation of this process can involve impaired recruitment of clathrin and adaptor proteins, altered membrane dynamics, or changes in vesicle trafficking that prevent delivery of cholesterol to downstream compartments. In vascular endothelium, such inhibition helps limit lipid accumulation under homeostatic conditions.
Integration with cellular cholesterol status
In simple terms: When the cell already has enough cholesterol, it puts the brakes on further uptake.
Cells sense cholesterol levels and adjust receptor-mediated endocytosis accordingly. Negative regulation of cholesterol transport is part of a feedback system that prevents excessive cholesterol influx when intracellular stores are sufficient. This integration ensures that cholesterol uptake is matched to metabolic demand and helps avoid the pathological consequences of cholesterol overload in tissues such as the arterial wall.
Key Genes Involved in GO:1905601 negative regulation of receptor-mediated endocytosis involved in cholesterol transport
The following genes and proteins are central to the regulation of receptor-mediated endocytosis involved in cholesterol transport, based on their established roles in lipoprotein uptake and vascular biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LDLR | Primary receptor for LDL cholesterol uptake | Central to cholesterol transport and atherosclerosis models |
| PCSK9 | Promotes LDLR degradation, reducing uptake | Therapeutic target for lowering LDL cholesterol |
| IDOL | E3 ubiquitin ligase that targets LDLR for degradation | Negative regulator of LDLR availability |
| ARH | Adaptor protein required for LDLR endocytosis | Mutations cause familial hypercholesterolemia |
| CLTC | Clathrin heavy chain, forms coated pits | Required for receptor-mediated endocytosis |
| AP2M1 | Adaptor protein 2 subunit, links receptors to clathrin | Controls endocytic vesicle formation |
| MYLIP | Alternative name for IDOL, regulates LDLR stability | Modulates cholesterol uptake |
| SCARB1 | Scavenger receptor for HDL and other lipoproteins | Influences cholesterol transport in endothelium |
| ABCA1 | Cholesterol efflux pump | Balances uptake and efflux in vascular cells |
| ABCG1 | Cholesterol efflux transporter | Maintains cellular cholesterol homeostasis |
| NR1H2 | LXR beta, regulates cholesterol metabolism genes | Links lipid sensing to endocytosis |
| NR1H3 | LXR alpha, controls cholesterol efflux and uptake | Transcriptional regulator of cholesterol balance |
| SREBF2 | Master transcription factor for cholesterol synthesis and uptake | Coordinates LDLR expression |
| INSIG1 | Regulates SREBP processing | Indirectly affects LDLR levels |
| HMGCR | Rate-limiting enzyme in cholesterol synthesis | Cross-talk with uptake pathways |
| CETP | Transfers cholesteryl esters between lipoproteins | Modulates circulating cholesterol |
| APOB | Structural protein of LDL particles | Ligand for LDLR |
How Is negative regulation of receptor-mediated endocytosis involved in cholesterol transport Regulated?
The negative regulation of receptor-mediated endocytosis involved in cholesterol transport is itself regulated at multiple levels. Transcriptional control by SREBP-2 adjusts LDLR expression according to cellular sterol status, while post-translational mechanisms such as PCSK9-mediated degradation and IDOL-mediated ubiquitination rapidly reduce receptor availability. Inflammatory signals can also influence these pathways; for example, endotoxin exposure alters intestinal function and systemic metabolism, which may indirectly affect cholesterol handling. In vascular endothelium, shear stress and inflammatory cytokines modulate endothelial lipid uptake and retention, contributing to atherosclerosis. Together, these layers of regulation ensure that cholesterol uptake is tuned to metabolic demand and environmental cues.
negative regulation of receptor-mediated endocytosis involved in cholesterol transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LDLR | Familial hypercholesterolemia, atherosclerosis | LDLR knockout hepatocytes or endothelial cells |
| PCSK9 | Hypercholesterolemia, cardiovascular risk | PCSK9 overexpression or point-mutation models |
| IDOL | Cholesterol uptake regulation | IDOL knockout or overexpression cell lines |
| ARH | Familial hypercholesterolemia | ARH knockout cells to study LDLR trafficking |
| SCARB1 | HDL metabolism, atherosclerosis | SCARB1 knockout endothelial models |
Atherosclerosis and cardiovascular disease
Atherosclerosis is characterized by endothelial dysfunction and the accumulation of lipoproteins in the arterial wall. Negative regulation of receptor-mediated endocytosis involved in cholesterol transport influences how much LDL is internalized by endothelial and other vascular cells, thereby affecting plaque development. Dysregulation of this process can promote lipid retention and inflammation, key features of atherosclerotic lesions.
Familial hypercholesterolemia
Mutations in genes such as LDLR and ARH impair receptor-mediated endocytosis of LDL, leading to severely elevated plasma cholesterol and premature cardiovascular disease. While these mutations primarily affect the positive arm of uptake, they highlight the importance of the regulatory balance captured by GO:1905601. Understanding negative regulation can inform therapeutic strategies that modulate residual receptor activity.
Inflammation and metabolic dysfunction
Inflammatory states, including those triggered by endotoxin, can disrupt intestinal function and systemic lipid metabolism. Such disruptions may alter the regulation of cholesterol transport and contribute to metabolic dysfunction. Studying GO:1905601 in the context of inflammation could reveal how infection and inflammation influence cholesterol handling.
From negative regulation of receptor-mediated endocytosis involved in cholesterol transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase LDL uptake? | CRISPR knockout in HepG2 or endothelial cells |
| Does a specific mutation alter receptor degradation? | Point-mutation knock-in of LDLR or PCSK9 |
| Can a tag reveal receptor trafficking? | Tagged knock-in of LDLR with fluorescent protein |
| Does overexpression of a regulator reduce endocytosis? | Overexpression of IDOL or PCSK9 |
| Which genes modify cholesterol transport in endothelium? | CRISPR library screening in endothelial cells |
| How does inflammation affect cholesterol uptake? | Endotoxin-treated intestinal or endothelial models |
How to Study the negative regulation of receptor-mediated endocytosis involved in cholesterol transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on cholesterol uptake | Identify required genes |
| Point-mutation knock-in | Effect of specific amino acid changes | Dissect receptor domains |
| Fluorescent LDL uptake | Rate of receptor-mediated endocytosis | Quantify cholesterol transport |
| Live-cell imaging | Receptor trafficking and localization | Visualize endocytic steps |
| RNA-seq | Transcriptional changes after perturbation | Discover regulatory networks |
| Proteomics | Protein abundance and modifications | Identify post-translational regulation |
| CRISPR library screening | Unbiased gene discovery | Find modifiers of cholesterol transport |
| Endotoxin challenge assays | Inflammatory impact on lipid handling | Model infection-related metabolic changes |
CRISPR knockout and point-mutation screens
CRISPR knockout and point-mutation approaches allow precise disruption of genes involved in cholesterol transport regulation. These models can be used to test whether a candidate gene is required for negative regulation of LDLR-mediated endocytosis. Pooled screens enable unbiased discovery of modifiers of cholesterol uptake in relevant cell types.
Biochemical uptake assays
Ligand uptake assays using fluorescently labeled LDL measure the rate and extent of receptor-mediated endocytosis. Comparing control and genetically modified cells reveals the impact of specific genes on cholesterol transport. These assays are quantitative and can be adapted to high-throughput formats.
Imaging of receptor trafficking
Fluorescence microscopy and live-cell imaging track the localization and movement of LDLR and associated proteins. Tagged knock-in models allow visualization of receptor internalization and recycling in real time. Imaging can reveal whether negative regulation acts at the cell surface or in intracellular compartments.
Transcriptomic and proteomic profiling
RNA-seq and proteomics identify global changes in gene expression and protein abundance upon perturbation of cholesterol transport regulators. These methods can uncover feedback loops and compensatory pathways. Integrating multi-omics data helps build a systems-level view of GO:1905601.
How CRISPR Can Be Used to Study GO:1905601 negative regulation of receptor-mediated endocytosis involved in cholesterol transport
Knockout
CRISPR knockout of genes such as LDLR, PCSK9, or IDOL creates cell models to test their roles in negative regulation of cholesterol transport. Knockout endothelial or hepatic cells can be used to measure changes in LDL uptake and receptor trafficking. These models are foundational for causal inference in cholesterol biology.
Point Mutation
Point mutations introduced by CRISPR base editing or homology-directed repair allow fine mapping of functional domains in receptors and regulators. For example, mutating specific residues in LDLR or PCSK9 can reveal their roles in endocytosis and degradation. Such models are valuable for studying disease-associated variants.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous loci enables tracking of receptor dynamics under native regulation. Tagged LDLR or IDOL can be visualized in live cells to study trafficking and turnover. Knock-in models also allow expression of mutant proteins at physiological levels.
Overexpression
Overexpression of negative regulators such as IDOL or PCSK9 reduces LDLR levels and cholesterol uptake, mimicking a brake on endocytosis. These models help test whether increasing a regulator is sufficient to alter cholesterol transport. Overexpression can be combined with uptake assays to quantify effects.
How EDITGENE Supports negative regulation of receptor-mediated endocytosis involved in cholesterol transport Research
Researchers studying negative regulation of receptor-mediated endocytosis involved in cholesterol transport-related genes often need to determine whether a candidate gene is causally involved in controlling cholesterol uptake or is merely correlated with it. Establishing causality requires precise genetic manipulation and functional readouts in relevant cell models. EDITGENE provides the tools and services to build such models efficiently and reproducibly.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of receptor-mediated endocytosis involved in cholesterol transport research.
Frequently Asked Questions About negative regulation of receptor-mediated endocytosis involved in cholesterol transport
What is GO:1905601?
GO:1905601 is a Gene Ontology biological process term for any process that stops, prevents, or reduces the frequency, rate, or extent of receptor-mediated endocytosis involved in cholesterol transport.
What genes are involved in negative regulation of receptor-mediated endocytosis involved in cholesterol transport?
Key genes include LDLR, PCSK9, IDOL (MYLIP), ARH, and clathrin-associated machinery such as CLTC and AP2M1.
How does negative regulation of LDL uptake work?
It reduces the number of available LDL receptors, interferes with receptor clustering, or impairs endocytic vesicle formation, thereby limiting cholesterol internalization.
Why is this process important in atherosclerosis?
By controlling how much LDL is taken up by vascular cells, this process influences lipid accumulation and plaque formation in arteries.
What diseases are linked to defects in cholesterol transport regulation?
Atherosclerosis, familial hypercholesterolemia, and inflammation-associated metabolic dysfunction are linked to altered cholesterol transport regulation.
How can CRISPR help study GO:1905601?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes that regulate cholesterol uptake.
What cell models are suitable for studying this process?
HepG2, endothelial cells, and other cholesterol-handling cell lines are commonly used, with genetic modifications to test specific genes.
What methods measure receptor-mediated endocytosis of cholesterol?
Fluorescent LDL uptake assays, live-cell imaging, and biochemical trafficking assays are standard methods.
Does inflammation affect cholesterol transport regulation?
Yes, inflammatory signals such as endotoxin can alter intestinal function and systemic lipid handling, indirectly affecting cholesterol transport.
Can EDITGENE provide custom models for this pathway?
Yes, EDITGENE offers knockout, point-mutation, knock-in, overexpression, and library screening services tailored to cholesterol transport research.
Conclusion
GO:1905601 defines a critical regulatory node that controls how cells take up cholesterol via receptor-mediated endocytosis. Its proper function is essential for cholesterol homeostasis, and its dysregulation contributes to atherosclerosis and related metabolic disorders. Understanding the genes and mechanisms involved provides a foundation for therapeutic strategies and for interpreting disease-associated variants. With advanced CRISPR tools and functional assays, researchers can now dissect this process with unprecedented precision.
References
- 1. Sima AV et al.. 2009. Vascular endothelium in atherosclerosis.. Cell Tissue Res 335(1):191-203 PMID: 18797930
- 2. Mani V et al.. 2012. Growth and Development Symposium: Endotoxin, inflammation, and intestinal function in livestock.. J Anim Sci 90(5):1452-65 PMID: 22247110
